BACKGROUND AND PURPOSE: Despite the potent tumoricidal activity of the synthetic dsRNA in culture, its in vivo anti-tumor activity has proven to be limited. We sought to devise and validate a new strategy to improve the in vivo anti-tumor activity by integrating localized irradiation into dsRNA therapy. MATERIALS AND METHODS: Using a mouse lung cancer model and a mouse melanoma model in immuno-competent mice or athymic nude mice, we evaluated the combined anti-tumor activity using a synthetic dsRNA, polyinosine-cytosine (poly(I:C)). RESULTS: Localized irradiation of tumors prior to the poly(I:C) therapy significantly delayed the tumor growth as compared to monotherapies using the radiation or poly(I:C) alone. The poly(I:C) enhanced the tumor response to radiation with a dose modification factor as large as 20. The combined effect was synergistic only in immuno-competent mice with highly immunogenic tumors. The anti-tumor activity of the combination therapy was significantly impaired when the type I interferons in the mice were neutralized. CONCLUSIONS: This combination modality may represent a promising approach to exploit synthetic dsRNA in cancer therapy and to enhance tumor response to radiation. T cell-mediated immunity was likely responsible for the combined synergistic effect. Type I interferons contributed significantly to the combined anti-tumor activity.
BACKGROUND AND PURPOSE: Despite the potent tumoricidal activity of the synthetic dsRNA in culture, its in vivo anti-tumor activity has proven to be limited. We sought to devise and validate a new strategy to improve the in vivo anti-tumor activity by integrating localized irradiation into dsRNA therapy. MATERIALS AND METHODS: Using a mouselung cancer model and a mousemelanoma model in immuno-competent mice or athymicnude mice, we evaluated the combined anti-tumor activity using a synthetic dsRNA, polyinosine-cytosine (poly(I:C)). RESULTS: Localized irradiation of tumors prior to the poly(I:C) therapy significantly delayed the tumor growth as compared to monotherapies using the radiation or poly(I:C) alone. The poly(I:C) enhanced the tumor response to radiation with a dose modification factor as large as 20. The combined effect was synergistic only in immuno-competent mice with highly immunogenic tumors. The anti-tumor activity of the combination therapy was significantly impaired when the type I interferons in the mice were neutralized. CONCLUSIONS: This combination modality may represent a promising approach to exploit synthetic dsRNA in cancer therapy and to enhance tumor response to radiation. T cell-mediated immunity was likely responsible for the combined synergistic effect. Type I interferons contributed significantly to the combined anti-tumor activity.
Authors: H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira Journal: Nature Date: 2000-12-07 Impact factor: 49.962
Authors: Luka Milas; Kathryn A Mason; Hisanori Ariga; Nancy Hunter; Robert Neal; David Valdecanas; Arthur M Krieg; John K Whisnant Journal: Cancer Res Date: 2004-08-01 Impact factor: 12.701
Authors: Ruud P M Dings; Yumi Yokoyama; Sundaram Ramakrishnan; Arjan W Griffioen; Kevin H Mayo Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: Sandra Demaria; Bruce Ng; Mary Louise Devitt; James S Babb; Noriko Kawashima; Leonard Liebes; Silvia C Formenti Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-01 Impact factor: 7.038
Authors: Tiffany C Blair; Shelly Bambina; Alejandro F Alice; Gwen F Kramer; Terry R Medler; Jason R Baird; Miranda L Broz; Garth W Tormoen; Victoria Troesch; Marka R Crittenden; Michael J Gough Journal: J Immunol Date: 2020-04-27 Impact factor: 5.422
Authors: B Leticia Rodriguez; Jorge M Blando; Dharmika S P Lansakara-P; Yuriko Kiguchi; John DiGiovanni; Zhengrong Cui Journal: Mol Pharm Date: 2013-05-17 Impact factor: 4.939